Biological operational amplifier and biological operational amplification system
By using a mathematical model and negative feedback loop constructed with orthogonal and inhibitory factors in a biological operational amplifier, the interference and crosstalk problems of non-orthogonal signals in biological systems were solved, achieving signal orthogonality and precise control, and improving the sensitivity and specificity of signal processing.
Patent Information
- Application Number
- PCT/CN2025/093793
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Non-orthogonal signal interference and crosstalk in existing biological systems make precise control difficult, especially when dealing with multidimensional complex signals, signal interpretation and control are complicated.
A biological operational amplifier is used to construct a mathematical model through the linear interaction of orthogonal activators and inhibitors to linearly amplify and decouple non-orthogonal biological signals. Combined with a negative feedback loop and a pre-built promoter library, the orthogonalization and precise control of the signals are achieved.
Effective decoupling and signal processing avoids interference and crosstalk between signal paths, ensuring accurate signal processing, achieving higher sensitivity and specificity, and improving the efficiency and accuracy of signal processing.
Smart Images

Figure CN2025093793_12112026_PF_FP_ABST
Abstract
Description
Bio-operational amplifier and bio-operational amplifier system Technical Field
[0001] This application relates to the fields of synthetic biology and genetic engineering, and in particular to a biological operational amplifier and a biological operational amplifier system. Background Technology
[0002] Genetic circuits in biological systems regulate cellular behavior, maintain homeostasis, and respond to external stimuli through complex gene-protein interactions. However, signals in natural biological systems are typically non-orthogonal, meaning that signaling pathways are not completely independent. Unlike traditional electronic signals, signals in biological systems are not simply "on" and "off" states, but rather change with variations in the environment and cellular state. This non-orthogonality makes signal interpretation and precise control extremely complex, especially when dealing with multidimensional and complex signals, where signal interference and overlap further increase the challenges. Summary of the Invention
[0003] In view of this, this application provides a biological operational amplifier and a biological operational amplification system to solve the problem that interference and crosstalk of non-orthogonal signals in existing gene circuits make it difficult to accurately control the system.
[0004] To solve the above-mentioned technical problems, one technical solution adopted in this application is: to provide a biological operational amplifier, which includes: at least one pair of orthogonal activators and inhibitors, wherein the activators and inhibitors form an inactive complex through linear interaction, and the biological operational amplifier is used to linearly amplify and decouple non-orthogonal biological signals based on a mathematical model constructed by the linear interaction of the activators and inhibitors, so as to obtain orthogonal output signals.
[0005] As a further improvement to this application, the mathematical model is expressed as: X E =α·X1-β·X2;
[0006] Among them, X E X1 and X2 represent the intensity of the effective signal, respectively, while α and β represent the intensity of the input biological signal. d R represents the scaling gain, r1 represents the translation rate at the ribosome binding site of the activator, γ1 represents the degradation rate at the ribosome binding site of the activator, r2 represents the translation rate at the ribosome binding site of the repressor, γ2 represents the degradation rate at the ribosome binding site of the repressor, and O represents the output signal. max K represents the gain parameter modulated using the maximum output signal, and K2 is the binding constant of the activation factor.
[0007] As a further improvement to this application, it also includes a negative feedback loop, and the output signal after introducing the negative feedback loop is expressed as:
[0008] As a further improvement of this application, the ratio of the regulation parameters α to β is finely tuned based on a bicistronic design to adjust the strength of the ribosome binding sites of the activator and repressor, so that the biooperational amplifier operates within its effective functional range.
[0009] As a further improvement of this application, the activator and the repressor have similar linear properties and a Hill coefficient of 1.
[0010] As a further improvement of this application, the biological signal includes a promoter, and the biological operational amplifier also includes a pre-constructed promoter library, which includes a pre-expression promoter and a post-expression promoter. The exponential phase expression intensity of the pre-expression promoter is greater than the plateau phase expression intensity, and the exponential phase expression intensity of the post-expression promoter is less than the plateau phase expression intensity.
[0011] As a further improvement to this application, the promoter library construction process includes: based on natural prokaryotic RNA-seq data analysis, extracting specific expression characteristics of different growth stages, and then designing promoters using these specific expression characteristics; defining pre-expression promoters and post-expression promoters based on the relationship between the ratio of the exponential phase intensity to the plateau phase intensity of the promoter and a preset ratio threshold, wherein the ratio of the exponential phase intensity to the plateau phase intensity of the pre-expression promoter exceeds the preset ratio threshold, and the ratio of the exponential phase intensity to the plateau phase intensity of the post-expression promoter does not exceed an even number of preset ratio thresholds; constructing a pre-expression promoter containing a GC-containing DISC region and a "TATAAT" sequence, and wherein the -13nt region is not C, and constructing a post-expression promoter containing an AT-containing DISC region, being rich in C at the -13nt and -36nt positions, and having a "TATACT" sequence in the -10 region.
[0012] To solve the above-mentioned technical problems, another technical solution adopted in this application is: to provide a single-dimensional biological operational amplification system, which includes: an input module for receiving at least one externally input biological signal and quantizing the biological signal; a biological operational amplifier of one of the above, which is used to linearly amplify and decouple the quantized biological signal to obtain an output signal; and an output module for regulating the expression of a target gene according to the output signal to achieve the regulatory target of the gene circuit.
[0013] To solve the above-mentioned technical problems, another technical solution adopted in this application is: providing a multi-dimensional biological operational amplification system, characterized in that it includes: an input module for receiving multiple externally input biological signals and quantifying the biological signals to obtain an input signal matrix; multiple biological operational amplifiers of one of the above, the biological operational amplifiers being used to perform orthogonal signal transformation and matrix operations on the biological signals in the input signal matrix to obtain an output signal matrix, wherein the diagonal elements of the output signal matrix retain the expression level and the off-diagonal elements are set to 0; and an output module for regulating the expression of target genes according to the output signal matrix to achieve the regulatory target of gene circuits.
[0014] As a further improvement of this application, the matrix operation includes decomposing the input signal matrix constructed from the biological signal into an output signal matrix through a pre-constructed decoding matrix. The decoding matrix is obtained by performing a Hadamard product operation on the coefficient matrix constructed using the control parameters of the biological operational amplifier and the pre-constructed scaling matrix. The scaling matrix is constructed by scaling without changing the characteristics of the biological signal.
[0015] The beneficial effects of this application are as follows: The biological operational amplifier of this application is constructed based on orthogonal activators and inhibitors. By using linear transformation and matrix operation techniques, non-orthogonal biological signals are decomposed into orthogonal signals, thereby effectively decoupling and processing signals, avoiding interference and crosstalk between signal pathways, ensuring accurate signal processing, and achieving higher sensitivity and specificity through precise control of signal decoupling, thus ensuring the efficiency and accuracy of signal processing. Attached Figure Description
[0016] Figure 1 is a schematic diagram of the model structure of the biological operational amplifier according to an embodiment of the present invention;
[0017] Figure 2 is a schematic diagram of the biological operational amplifier according to an embodiment of the present invention;
[0018] Figure 3 is a schematic diagram of the open-loop circuit of the biological operational amplifier according to an embodiment of the present invention;
[0019] Figure 4 is a closed-loop circuit diagram of the biological operational amplifier according to an embodiment of the present invention;
[0020] Figure 5 is a schematic diagram illustrating the effect of adjusting the ribosome binding site (RBS) on the performance of the operational amplifier according to an embodiment of the present invention.
[0021] Figure 6 is a schematic diagram illustrating the effect of the input vector angle on the performance of the biological operational amplifier according to an embodiment of the present invention.
[0022] Figure 7 is a schematic diagram comparing the expression characteristics of the natural promoter before and after in an embodiment of the present invention;
[0023] Figure 8 is a schematic diagram illustrating the effect of DISC on the before and after representations of the present invention;
[0024] Figure 9 is a schematic diagram showing the effect of the -10 region on the before and after representations of the present invention;
[0025] Figure 10 is a schematic diagram showing the effect of the extended-10 region on the before and after representations of the present invention.
[0026] Figure 11 is a pie chart showing all the influencing factors before and after the embodiments of the present invention;
[0027] Figure 12 is a graph showing the experimental results of the natural pre- and post-expression promoters in an embodiment of the present invention.
[0028] Figure 13 is a schematic diagram of the structure of the single-dimensional biological computing amplification system according to an embodiment of the present invention;
[0029] Figure 14 is a schematic diagram of the structure of the multi-dimensional biological computing amplification system according to an embodiment of the present invention;
[0030] Figure 15 is a schematic diagram of the N-dimensional signal processing principle of the multi-dimensional signal processing device according to an embodiment of the present invention;
[0031] Figure 16 is a three-dimensional crosstalk principle diagram of the multi-dimensional signal processing device according to an embodiment of the present invention;
[0032] Figure 17 is a schematic diagram of the principle of shikimic acid accumulation achieved by the pre-expression functional circuit in an embodiment of the present invention;
[0033] Figure 18 is a graph showing the shikimic acid production and cell growth of the pre-expression functional circuit in an embodiment of the present invention.
[0034] Figure 19 is a schematic diagram of the protein expression principle achieved by the post-expression functional circuit in an embodiment of the present invention;
[0035] Figure 20 is a schematic diagram of the expression growth curve of post-expression functional circuit protein in an embodiment of the present invention. Detailed Implementation
[0036] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of this application, and not all of the embodiments. Based on the embodiments of this application, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this application.
[0037] The terms "first," "second," and "third" in this application are for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first," "second," or "third" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified. All directional indications (such as up, down, left, right, front, back, etc.) in the embodiments of this application are only used to explain the relative positional relationships and movements between components in a specific orientation (as shown in the figures). If the specific orientation changes, the directional indications also change accordingly. Furthermore, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to these processes, methods, products, or devices.
[0038] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a separate or alternative embodiment mutually exclusive with other embodiments. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.
[0039] This invention provides a specific embodiment of a biological operational amplifier. The biological operational amplifier includes at least one pair of orthogonal activators and repressors, which form an inactive complex through linear interactions. The biological operational amplifier is used to linearly amplify and decouple non-orthogonal biological signals based on a mathematical model constructed from the linear interactions of the activators and repressors, as shown in Figure 1, to obtain orthogonal output signals.
[0040] This invention designs a biological operational amplifier based on the interaction between σ-factors (activators) and anti-σ-factors (inhibitors). The biological signal includes at least one of the following: light, chemical signals, temperature, growth signals, etc., without limitation herein.
[0041] It should be noted that, as shown in Figure 2, which illustrates the operational amplifier schematic, the input signal is abstracted into a two-dimensional form (x, y). Taking the promoter as an example, the expression levels correspond to the exponential and stable periods, respectively. In this invention, the exponential period expression level being higher than the stable period is called the pre-expression, and the exponential period expression level being lower than the stable period is called the post-expression. Through linear operations such as subtraction and multiplication scaling, these signals are decomposed into orthogonal signals. The decomposition process is expressed as follows:
[0042] in, For the input matrix, The coefficient matrix, This is the output matrix.
[0043] Operational amplifiers can perform α·I1-β·I2 operations on input signals, thereby ensuring the linearization of the activation-inhibition relationship. Therefore, this invention constructs a linear biological operational amplifier based on good linear interactions and orthogonality, utilizing orthogonal σ factors and corresponding anti-σ factors.
[0044] Furthermore, in this embodiment, ECF (ECF is a special family of σ factors in prokaryotes, full name ExtraCytoplasmic Function σ factors)) and T7 RNA polymerase (T7 RNAP) and its inhibitor T7 lysozyme can be selected for construction.
[0045] Assuming the σ factor is A and the anti-σ factor is R, the reaction will produce an inactive compound AR, and the reaction satisfies the following equation:
[0046] The concentrations of A and R need to be subtracted from the concentration of AR: [A] = [A0] - [AR], [R] = [R0] - [AR];
[0047] Where [A0] represents the initial concentration of the activator and [R0] represents the initial concentration of the repressor, determined by the intensity of the input biological signal X1 and X2. The generation of activator protein A and repressor protein R is regulated by the translation rates r1 and r2 of the ribosome binding site RBS and the corresponding degradation rates γ1 and γ2.
[0048] Where r1 represents the translation rate of the ribosome binding site of the activator, γ1 represents the degradation rate of the ribosome binding site of the activator, r2 represents the translation rate of the ribosome binding site of the repressor, and γ2 represents the degradation rate of the ribosome binding site of the repressor.
[0049] Based on the equilibrium reaction (1), the following quadratic equation can be obtained: K1[AR]2 -(K[A0]+K1[R0]+1)[AR]+K1[A0][R0]=0;
[0050] The solution can be obtained as:
[0051] When K1→∞, it can be simplified as:
[0052] When K1→∞ and [A0]≥[R0], the effective activated protein concentration X E has the following calculation formula: X E =α·X1-β·X2(4)
[0053] The output of the gene circuit follows the following equation, with a Hill coefficient of 1:
[0054] where O denotes the output signal, O max denotes the gain parameter modulated by the maximum output signal, and K2 is the binding constant of the activator. This formula indicates that although X E is the result of a linear operation of X1 and X2, the output O is not the result of a linear operation of X1 and X2, and the output is a linear operation process of the input only when X E <<K2. Therefore, the linear range of the gene circuit is positively correlated with the binding constant K2. In addition, the gain parameter O max is determined by the binding strength of the activator and the biological signal. The effective functional interval of the gene circuit refers to the -3dB standard of the effective bandwidth of an electronic circuit, that is, the output signal is reduced to half of the maximum value, representing the minimum effective bandwidth of the system operation error. Taking the open-loop gene circuit OA O (E22.14.21.P ECF22 ) as an example, different external inducers and carbonic anhydrase concentration gradients are used for induction, as the positive and negative inputs of the circuit. Fitting is performed based on formulas (4) and (5) to obtain the main parameters α, β, O max , and K2 of the biological operational amplifier, thereby completing the construction of the biological operational amplifier, which is specifically expressed as:
[0055] In addition, the present invention also introduces the concept of signal-to-noise ratio SNR, which is used to measure the performance of the biological operational amplifier, that is, the ratio of the effective signal to the ineffective signal, namely the ratio of the output in the target direction to the output in the non-target direction:
[0056] where effective signal denotes the effective signal, noise denotes the ineffective signal, O target denotes the output in the target direction, and O off-target denotes the output in the non-target direction.
[0057] The bio-operational amplifier in this embodiment is constructed based on orthogonal activators and inhibitors. By using linear transformation and matrix operation techniques, non-orthogonal biological signals are decomposed into orthogonal signals, thereby effectively decoupling and processing signals, avoiding interference and crosstalk between signal pathways, ensuring accurate signal processing, and achieving higher sensitivity and specificity through precise control of signal decoupling, ensuring high efficiency and accuracy in signal processing.
[0058] Furthermore, in this embodiment, the activator and the repressor have similar linear properties and a Hill coefficient of 1.
[0059] Furthermore, to improve the stability and robustness of the system, the present invention introduces a negative feedback loop into the open-loop bio-operational amplifier system in the above embodiments.
[0060] Specifically, as shown in Figures 3 and 4, Figure 3 illustrates an example of an open-loop bio-operational amplifier, and Figure 4 illustrates an example of a bio-operational amplifier with an added negative feedback loop. In the closed-loop bio-operational amplifier, the output signal is represented as:
[0061] Among them, X A This represents the concentration of the corresponding inhibitor activated by the additional activator generated by negative feedback. Based on X E =α·X1-β·X2, the above equation can be simplified to:
[0062] Solving for the given information yields:
[0063] Based on the first-order Taylor expansion, we can obtain:
[0064] It should be noted that in the actual construction process, it is also necessary to select appropriate biological signals according to the actual application requirements. For example, the biological operational amplifier in the above embodiment uses P... ECF22 (One type of promoter) is used as an example for construction, but P ECF22 The performance of P is not well supported for the construction of negative feedback circuits. Therefore, this embodiment uses P. ECF22M1 (P ECF22 A mutant of the promoter was constructed. The output O of the closed-loop circuit can be solved by solving the following set of equations simultaneously:
[0065] Solving for the given information yields:
[0066] The formula for calculating K′ is as follows: K′=K ECF22 / K ECF22M1 (8)
[0067] Among them, K ECF22 P represents ECF22 The binding constant, K ECF22M1 P represents ECF22M1 The binding constant.
[0068] This embodiment introduces a negative feedback mechanism into an open-loop biological operational amplifier system, forming a closed-loop circuit to regulate the effective activator concentration. The addition of negative feedback effectively extends the system's linear operating range and significantly improves its noise suppression capability. In the optimized closed-loop system, the output signal's response to the input signal is more precise, and signal stability is also improved.
[0069] Furthermore, in the above embodiments, the ratio of regulating parameters α to β is finely tuned based on bicistronic design to adjust the strength of the ribosome binding sites of the activator and repressor, so that the biological operational amplifier operates within its effective functional range.
[0070] It should be noted that due to the limitation of the α / β ratio in the biological operational amplifier, the amplifier may fall into the non-functional region where the target output is negative due to growth pressure or insufficient strength of the input biological signal. To solve this problem, this embodiment fine-tunes the strength of the ribosome binding sites of the activator and repressor by adjusting the ratio of the α and β parameters through a bicistronic design, so that the biological operational amplifier operates within its effective functional range. Specifically, this embodiment uses BCD2(A), BCD2(R), BCD7(A), and BCD18(R) as examples. Referring to Figure 5, the stars outside the shaded area indicate that the biological operational amplifier falls into the non-functional region where the target output is negative. By replacing the original RBS pairs BCD2(A) and BCD2(R) with BCD7(A) and BCD18(R), the α / β ratio is adjusted, and the target output of the biological operational amplifier is successfully moved into the effective region (the stars in the shaded area in Figure 5). Furthermore, in order to achieve efficient signal processing in various biological systems, based on the above embodiments, in other embodiments, the biological signal includes a promoter, and the biological operational amplifier also includes a pre-constructed promoter library. The promoter library includes pre-expression promoters and post-expression promoters. The exponential phase expression intensity of the pre-expression promoter is greater than the plateau phase expression intensity, and the exponential phase expression intensity of the post-expression promoter is less than the plateau phase expression intensity.
[0071] Specifically, this embodiment uses a promoter as a biological signal for illustration. It is understood that this biological signal can also be parameters such as light, chemical signals, temperature, or growth signals; this embodiment is not limited to these. It should be noted that this embodiment analyzes the expression pattern and performance of the promoter. Please refer to Figure 6, which shows the influence of the input vector angle on the operational amplifier performance. As shown in Figure 6, the output is affected by three variables: α, E1, and tanθ1-tanθ2. Large values of α and E1 can lead to growth pressure; therefore, increasing tanθ1-tanθ2 will result in a larger output vector value, i.e., increasing the input vector angle. To study the influencing factors of the input vector angle, this embodiment analyzes natural E. coli RNAseq and extracts promoters, obtaining the characteristics of pre-expression and post-expression promoters, as shown in Figure 7. In this invention, promoters with exponential phase expression intensity greater than stationary phase expression intensity are defined as pre-expression promoters, and those with exponential phase expression intensity less than stationary phase expression intensity are defined as post-expression promoters.
[0072] For ease of analysis, an expression threshold n is introduced to vary the definition of the pre- and post-expression promoters. Promoters with an exponential phase intensity / stationary phase intensity greater than n are considered pre-expression promoters, while those with a stationary phase intensity / exponential phase intensity greater than n are considered post-expression promoters. The default value for n is 1.5. This embodiment uses RNAseq analysis of natural promoters to obtain numerous characteristic influencing factors of pre- and post-expression, including DISC influencing factors, the influence of the -10 region, and the influence of the extended -10 region, resulting in the results shown in Figures 8 to 11. Based on the above analysis, the post-expression promoter exhibits an AT-rich DISC region, C-rich positions at -13nt and -36nt, and a distinct "TATACT" motif in the -10 region. The pre-expression promoter displays a GC-rich DISC region and a typical "TATAAT" sequence, and the -13nt region does not contain C. Based on the above analysis results, this embodiment selects promoters with a large difference in pre- and post-expression ratios and consistent with these characteristics for experimental verification. The experimental results confirm the growth phase-specific expression pattern of the promoter, as shown in Figure 12. Based on this, this embodiment designed a promoter library containing specific characteristics of different promoter growth stages, and conducted experimental comparisons to confirm that the performance of the synthesized promoter library indeed showed a significant difference in expression before and after.
[0073] This embodiment constructs a promoter library that conforms to the promoter expression pattern characteristics obtained from the analysis of natural prokaryotic promoters, thereby protecting its application in gene expression regulation in synthetic biology and ensuring the system's high efficiency and wide applicability.
[0074] To further evaluate the application value of the promoter library, this embodiment uses synthetic and natural promoter pairs as inputs, integrates them into a biological operational amplifier, and systematically evaluates the performance of both under different configurations. The synthetic promoter pair consistently outperformed the natural promoter pair across all metrics, achieving higher scores. Therefore, the promoter library composed of synthetic promoters can provide abundant resources for subsequent gene circuit design, ensuring the flexibility and efficiency of the biological operational amplifier under various conditions.
[0075] Furthermore, the process of building the startup sub-library includes:
[0076] 1. Based on the analysis of natural prokaryotic RNA-seq data, specific expression characteristics at different growth stages are extracted, and promoters are designed using these specific expression characteristics.
[0077] 2. Based on the relationship between the ratio of the exponential phase intensity and the plateau phase intensity of the promoter and a preset ratio threshold, define the pre-expression promoter and the post-expression promoter. The ratio of the exponential phase intensity to the plateau phase intensity of the pre-expression promoter exceeds the preset ratio threshold, while the ratio of the exponential phase intensity to the plateau phase intensity of the post-expression promoter does not exceed an even number of preset ratio thresholds.
[0078] 3. Construct a pre-expression promoter containing a GC-containing DISC region and a "TATAAT" sequence, and whose -13nt is not C; and construct a post-expression promoter containing an AT-containing DISC region, rich in C at the -13nt and -36nt positions, and with a "TATACT" sequence in the -10 region.
[0079] Furthermore, based on the above embodiments, the parameters of the biological operational amplifier system are further optimized using the promoter library and RBS library from the above embodiments, combined with an optimal selection algorithm. By evaluating the performance of different promoter and RBS combinations, the optimal input signal pairing is selected to maximize signal processing efficiency. The specific process includes:
[0080] Step 1: Data Input and Parameter Initialization
[0081] Input the promoter library, which contains the relative promoter units (RPUs) of each promoter during the exponential and steady-state periods;
[0082] Input the RBS library, which contains the ribosome binding efficiency (REU) of each RBS;
[0083] Initialize the system parameters (α, β, K2, O) of the biological operational amplifier. max ARBS_ID, RRBS_ID) and constraints (threshold, min_expression).
[0084] Step 2: Combined Traversal and Parameter Adjustment
[0085] Traverse all combinations of activating promoters(P i ) and inhibitory promoters(P j );
[0086] For each pair of combinations, traverse all possible RBS pairs(RBS i for activators, RBS j for inhibitors);
[0087] Dynamically adjust the α and β parameters:
[0088] (Precise control of the α / β ratio is achieved through RBS regulation to optimize signal gain)
[0089] Step 3: Expression level prediction and screening
[0090] Call the prediction model to calculate the output signal:
[0091] Effective activator concentration: X E ←max(α·A-β·R,min_expression);
[0092] Output signal strength:
[0093] Filter combinations that cause excessive growth stress(if the predicted OD value < threshold, skip it).
[0094] Step 4: Performance scoring and ranking
[0095] Calculate a comprehensive score according to the preset scoring function(CalculateScore). The scoring criteria include:
[0096] Signal-to-noise ratio(SNR):
[0097] Dynamic range: the ratio of the exponential phase to the stationary phase;
[0098] Orthogonality score: orthogonality evaluation of the included angles of input signals.
[0099] Sort all valid combinations in descending order of score, and output the top n optimal configurations.
[0100] Step 5: Experimental verification and iterative optimization
[0101] Apply the screened optimal configurations to actual biological systems(such as Escherichia coli BL21 or MG1655);
[0102] Verify the performance through fluorescence detection, SDS-PAGE or metabolite analysis;
[0103] The experimental results are used to optimize the model parameters and achieve closed-loop iteration.
[0104] Furthermore, based on the above embodiments, as shown in FIG13, the present invention also provides a single-dimensional biological operational amplifier system, which includes: an input module 10, a biological operational amplifier 11 as described in one of the above embodiments, and an output module 12.
[0105] The input module 10 is used to receive at least one externally input biological signal and to quantify and express the biological signal.
[0106] The biological operational amplifier 11 is used to linearly amplify and decouple the quantized biological signal to obtain the output signal.
[0107] The output module 12 is used to regulate the expression of the target gene according to the output signal in order to achieve the regulatory target of the gene circuit.
[0108] The single-dimensional biological operational amplifier system of this embodiment uses the biological operational amplifier of one of the above embodiments to decompose non-orthogonal biological signals into orthogonal signals using linear transformation and matrix operation techniques. This effectively decouples and processes the signals, avoids interference and crosstalk between signal paths, ensures accurate signal processing, and achieves higher sensitivity and specificity by precisely controlling signal decoupling, thus ensuring the efficiency and accuracy of signal processing.
[0109] Furthermore, in order to eliminate crosstalk problems in multi-signal systems, based on the above embodiments, as shown in Figure 14, the present invention also provides a multi-dimensional biological operational amplifier system, which includes: an input module 20, a plurality of biological operational amplifiers 21 of one of the above embodiments, and an output module 22.
[0110] The input module 20 is used to receive multiple externally input biological signals and quantify the biological signals to obtain an input signal matrix.
[0111] Multiple biological operational amplifiers 21 are used to perform orthogonal signal transformation and matrix operations on the biological signals in the input signal matrix to obtain an output signal matrix. The diagonal elements of the output signal matrix retain the expression level, while the off-diagonal elements are set to 0.
[0112] Furthermore, the matrix operation includes decomposing the input signal matrix constructed from the biological signal into an output signal matrix through a pre-constructed decoding matrix. The decoding matrix is obtained by performing a Hadamard product operation on the coefficient matrix constructed using the control parameters of the biological operational amplifier and the pre-constructed scaling matrix. The scaling matrix is constructed by scaling without changing the characteristics of the biological signal.
[0113] The output module 22 is used to regulate the expression of the target gene according to the output signal matrix in order to achieve the regulatory target of the gene circuit.
[0114] Specifically, for multidimensional matrix operations, as shown in Figure 15, with N different input signals, after passing through a set of orthogonal signal transformations (OSTs), i.e., N operational amplifiers, the result can be an output matrix that is a diagonal matrix. All diagonal elements represent the expression level, and all other off-diagonal elements are 0, thus achieving signal decomposition for each growth state. In actual biological systems, negative signals generated by the operation can be replaced with 0.
[0115] This embodiment illustrates the use of three operational amplifiers to achieve crosstalk cancellation through matrix operations. The embodiment uses a quorum sensing (QS) system of LuxR (3-OC6HSL), LasR (3-OC12HSL), and CinR (3-OHC14HSL) as an example: Ideally, the Plux, Plas, and Pcin promoters should only respond to their homologous AHL molecules, producing perfectly orthogonal outputs. However, as shown in Figure 16, the natural coding mechanisms in these systems cause crosstalk in signal transmission, resulting in non-orthogonal responses. This embodiment employs a three-dimensional operational amplifier framework to decode and separate these cross-interacting signals. As shown in Figure 16, the decoding matrix can be calculated by associating the desired output matrix (orthogonal signals) with the input matrix (combination of AHL signals) and by using the inverse of the coding matrix, which represents the natural signal transmission in the quorum sensing system. However, the decoding matrix cannot be directly implemented using current biological operational amplifiers because the required α / β ratio is beyond the feasible range of existing gene circuitry. To address this issue, this embodiment decomposes the decoding matrix into an OA coefficient matrix and a promoter scaling matrix, which are then combined using a Hadamard product (element-wise product). The promoter strength is scaled without altering its functional characteristics, thereby constructing a promoter scaling matrix that meets the requirements of the decoding matrix. This ensures that the adjusted promoter strength retains its original inductive properties while achieving the scaling required for decoding.
[0116] This embodiment effectively separates cross-interference in multiple signal channels by constructing and optimizing orthogonal signal conversion circuits, ensuring independent control of each signal channel, thereby significantly improving the performance of the multi-signal system and enabling it to accurately process multidimensional signals in complex biological networks.
[0117] Furthermore, based on the above embodiments, the present invention also constructs a dynamically adjustable gene circuit, which is implemented based on the biological operational amplifier of the above embodiments and constructed using the above-described optimal component recommendation algorithm. The gene circuit includes a pre-expression functional circuit or a post-expression functional circuit.
[0118] Specifically, the pre-expression functional circuit activates target gene expression and redirects metabolic flow during the exponential phase, and shuts down metabolic bypasses during the plateau phase via the pre-expression promoter to accumulate the target product. The post-expression functional circuit activates target gene expression during the plateau phase and inhibits protein expression during the exponential phase via the post-expression promoter, thereby reducing growth stress.
[0119] Furthermore, based on the pre-expression functional circuit, this invention provides a metabolite production system based on the pre-expression functional circuit, applied to Escherichia coli MG1655 strain. It includes a pre-expression promoter and a pre-expression functional circuit. The pre-expression functional circuit activates metabolic pathway genes during the exponential phase to support cell growth and shuts down metabolic pathways during the plateau phase to directionally accumulate shikimic acid, dynamically regulating the aroK and aroL genes.
[0120] Specifically, in wild-type MG1655, shikimic acid (SA) is rapidly metabolized into aromatic amino acids via the aroK and aroL genes, preventing SA accumulation. Referring to Figure 17, this embodiment uses a pre-expression functional circuit to dynamically regulate aroK and aroL. These genes are expressed during the exponential growth phase to support growth, and shut down during the stationary phase to stop the pathway, thus achieving SA accumulation. The plateau phase in the figure represents the stationary phase. As shown in Figure 18, in aroK and aroL-deficient strains, the pre-expression functional circuit effectively controls SA production dynamics. During the exponential growth phase, the pre-expression functional circuit supports cell proliferation, while during the stationary phase, it redirects metabolic flow to achieve high SA accumulation. The pre-expression circuit achieves precise on / off switching, resulting in SA yields similar to other systems without the need for expensive inducers.
[0121] Furthermore, based on the post-expression functional circuit, this invention provides a protein expression system based on the post-expression functional circuit, applied to Escherichia coli BL21 strain, which includes a post-expression promoter and a post-expression functional circuit. The post-expression functional circuit inhibits the expression of the target protein during the exponential phase and activates the specific expression of LacI protein during the plateau phase.
[0122] Specifically, this embodiment uses a post-expression functional circuit for dynamic regulation. The same promoter shows different expression levels in BL21 and MG1655, and the parameters of the bio-operation amplifier also need to be recalibrated in M9-glucose and LB media. This embodiment performs OA in BL21. O (E22.18.21.P ECF22 ) and OA O (E22.7.21.P ECF22Induction tests were conducted to determine the coefficients of the corresponding biological operational amplifiers, and a new post-expression functional circuit was constructed based on these coefficients, as shown in Figure 19. As shown in Figure 20, the post-expression functional circuit was used to reduce the growth pressure of BL21 by not expressing it during the exponential phase, and to express it highly during the stationary phase to express the protein. The plateau phase in the figure represents the stationary phase.
[0123] The designed pre-expression and post-expression functional circuits were successfully applied in *E. coli* strains BL21 and MG1655 to achieve efficient expression of LacI protein and production of shikimic acid (SA). This demonstrates that the operational amplifier system can precisely control gene expression without external inducers and exhibits high stability and scalability.
[0124] The above are merely embodiments of this application and do not limit the scope of this patent application. Any equivalent structural or procedural changes made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the scope of patent protection of this application.
Claims
1. A biological operational amplifier, characterized in that, It includes: At least one pair of orthogonal activators and repressors, which form an inactive complex through linear interactions, are provided. The biological operational amplifier is used to linearly amplify and decouple non-orthogonal biological signals based on a mathematical model constructed by the linear interactions of the activators and repressors, to obtain orthogonal output signals.
2. The biological operational amplifier according to claim 1, characterized in that, The mathematical model is expressed as: X E =α·X1-β·X2; Among them, X E X1 and X2 represent the intensity of the effective signal, respectively, while α and β represent the intensity of the input biological signal. d R represents the scaling gain, r1 represents the translation rate at the ribosome binding site of the activator, γ1 represents the degradation rate at the ribosome binding site of the activator, r2 represents the translation rate at the ribosome binding site of the repressor, γ2 represents the degradation rate at the ribosome binding site of the repressor, and O represents the output signal. max K represents the gain parameter modulated using the maximum output signal, and K2 is the binding constant of the activation factor.
3. The biological operational amplifier according to claim 2, characterized in that, It also includes a negative feedback loop, and the output signal after introducing the negative feedback loop is expressed as:
4. The biological operational amplifier according to claim 2 or 3, characterized in that, The ratio of the regulation parameters α to β is fine-tuned based on a bicistronic design to control the strength of the ribosome binding sites of the activator and repressor, so that the bio-operational amplifier operates within its effective functional range.
5. The biological operational amplifier according to claim 1, characterized in that, The activator and the repressor have similar linear properties and a Hill coefficient of 1.
6. The biological operational amplifier according to claim 1, characterized in that, The biological signal includes a promoter, and the biological operational amplifier further includes a pre-constructed promoter library, which includes a pre-expression promoter and a post-expression promoter. The exponential phase expression intensity of the pre-expression promoter is greater than the plateau phase expression intensity, and the exponential phase expression intensity of the post-expression promoter is less than the plateau phase expression intensity.
7. The biological operational amplifier according to claim 6, characterized in that, The construction process of the startup sub-library includes: Based on the analysis of natural prokaryotic RNA-seq data, specific expression characteristics at different growth stages were extracted, and promoters were designed using these specific expression characteristics. Pre-expression promoters and post-expression promoters are defined based on the relationship between the ratio of the exponential phase intensity to the plateau phase intensity of the promoter and a preset ratio threshold. The ratio of the exponential phase intensity to the plateau phase intensity of the pre-expression promoter exceeds the preset ratio threshold, while the ratio of the exponential phase intensity to the plateau phase intensity of the post-expression promoter does not exceed an even number of preset ratio thresholds. A pre-expression promoter containing a GC-containing DISC region and a "TATAAT" sequence, and whose -13nt is not C, was constructed; and a post-expression promoter containing an AT-containing DISC region, rich in C at the -13nt and -36nt positions, and containing a "TATACT" sequence in the -10 region was constructed.
8. A single-dimensional biological amplification system, characterized in that, It includes: An input module is configured to receive at least one externally input biological signal and quantify the biological signal. The bio-operational amplifier according to any one of claims 1-7 is used to linearly amplify and decouple the quantized bio-signal to obtain an output signal; The output module is used to regulate the expression of the target gene according to the output signal in order to achieve the regulatory target of the gene circuit.
9. A multi-dimensional biological computing amplification system, characterized in that, It includes: The input module is used to receive multiple externally input biological signals and quantize the biological signals to obtain an input signal matrix; The biological operational amplifier according to any one of claims 1-7, wherein the biological operational amplifier is used to perform orthogonal signal transformation and matrix operation on the biological signals in the input signal matrix to obtain an output signal matrix, wherein the diagonal elements of the output signal matrix retain the expression level and the off-diagonal elements are set to 0; The output module is used to regulate the expression of the target gene according to the output signal matrix to achieve the regulatory target of the gene circuit.
10. The biological computational amplification system according to claim 9, characterized in that, The matrix operation includes decomposing the input signal matrix constructed from the biological signal into an output signal matrix through a pre-constructed decoding matrix. The decoding matrix is obtained by performing a Hadamard product operation using a coefficient matrix constructed from the control parameters of the biological operational amplifier and a pre-constructed scaling matrix. The scaling matrix is constructed by scaling without changing the characteristics of the biological signal.
